AmCad BioMed Corporation announced earnings results for the full year ended December 31, 2020. For the full year, the company announced sales was TWD 63.941 million compared to TWD 84.086 million a year ago. Operating loss was TWD 56.263 million compared to TWD 56.288 million a year ago. Net loss was TWD 35.444 million compared to TWD 37.741 million a year ago. Basic loss per share from continuing operations was TWD 0.67 compared to TWD 0.71 a year ago.